Vanda Pharmaceuticals PE Ratio 2006-2021 | VNDA

Current and historical p/e ratio for Vanda Pharmaceuticals (VNDA) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Vanda Pharmaceuticals PE ratio as of October 22, 2021 is 31.55.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Vanda Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 18.30 31.55
2021-06-30 21.51 $0.58 37.09
2021-03-31 15.02 $0.57 26.35
2020-12-31 13.14 $0.43 30.56
2020-09-30 9.66 $0.36 26.83
2020-06-30 11.44 $2.09 5.47
2020-03-31 10.36 $2.14 4.84
2019-12-31 16.41 $2.12 7.74
2019-09-30 13.28 $2.23 5.96
2019-06-30 14.09 $0.52 27.10
2019-03-31 18.40 $0.40 46.00
2018-12-31 26.13 $0.47 55.60
2018-09-30 22.95 $0.24 95.63
2018-06-30 19.05 $0.01 0.00
2018-03-31 16.85 $-0.11 0.00
2017-12-31 15.20 $-0.34 0.00
2017-09-30 17.90 $-0.31 0.00
2017-06-30 16.30 $-0.22 0.00
2017-03-31 14.00 $-0.30 0.00
2016-12-31 15.95 $-0.42 0.00
2016-09-30 16.64 $-0.76 0.00
2016-06-30 11.19 $-0.97 0.00
2016-03-31 8.36 $-0.99 0.00
2015-12-31 9.31 $-0.94 0.00
2015-09-30 11.28 $1.18 9.56
2015-06-30 12.69 $1.36 9.33
2015-03-31 9.30 $0.85 10.94
2014-12-31 14.32 $0.30 47.73
2014-09-30 10.38 $-1.70 0.00
2014-06-30 16.18 $-1.83 0.00
2014-03-31 16.25 $-1.30 0.00
2013-12-31 12.41 $-0.66 0.00
2013-09-30 10.95 $-0.66 0.00
2013-06-30 8.08 $-0.68 0.00
2013-03-31 3.92 $-0.85 0.00
2012-12-31 3.70 $-0.98 0.00
2012-09-30 4.03 $-0.95 0.00
2012-06-30 4.40 $-0.87 0.00
2012-03-31 4.79 $-0.64 0.00
2011-12-31 4.76 $-0.36 0.00
2011-09-30 4.95 $-0.08 0.00
2011-06-30 7.14 $0.14 51.00
2011-03-31 7.29 $0.23 31.70
2010-12-31 9.46 $0.25 37.84
2010-09-30 6.68 $-0.17 0.00
2010-06-30 6.61 $-0.56 0.00
2010-03-31 11.54 $-1.06 0.00
2009-12-31 11.25 $-1.32 0.00
2009-09-30 11.64 $-1.26 0.00
2009-06-30 11.77 $-1.39 0.00
2009-03-31 0.90 $-1.44 0.00
2008-12-31 0.50 $-1.92 0.00
2008-09-30 0.94 $-2.42 0.00
2008-06-30 3.29 $-2.83 0.00
2008-03-31 3.87 $-2.92 0.00
2007-12-31 6.88 $-2.81 0.00
2007-09-30 13.91 $-2.57 0.00
2007-06-30 20.26 $-2.30 0.00
2007-03-31 24.36 $-2.81 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.018B $0.248B
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76